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Abstract
Appropriate control of hepatic gluconeogenesis is essential for the organismal sur-
vival upon prolonged fasting and maintaining systemic homeostasis under metabolic 
stress. Here, we show protein arginine methyltransferase 1 (PRMT1), a key enzyme 
that catalyzes the protein arginine methylation process, particularly the isoform en-
coded by Prmt1 variant 2 (PRMT1V2), is critical in regulating gluconeogenesis in the 
liver. Liver-specific deletion of Prmt1 reduced gluconeogenic capacity in cultured 
hepatocytes and in the liver. Prmt1v2 was expressed at a higher level compared to 
Prmt1v1 in hepatic tissue and cells. Gain-of-function of PRMT1V2 clearly activated 
the gluconeogenic program in hepatocytes via interactions with PGC1α, a key tran-
scriptional coactivator regulating gluconeogenesis, enhancing its activity via argi-
nine methylation, while no effects of PRMT1V1 were observed. Similar stimulatory 
effects of PRMT1V2 in controlling gluconeogenesis were observed in human HepG2 
cells. PRMT1, specifically PRMT1V2, was stabilized in fasted liver and hepato-
cytes treated with glucagon, in a PGC1α-dependent manner. PRMT1, particularly 
Prmt1v2, was significantly induced in the liver of streptozocin-induced type 1 diabe-
tes and high fat diet-induced type 2 diabetes mouse models and liver-specific Prmt1 
deficiency drastically ameliorated diabetic hyperglycemia. These findings reveal 
that PRMT1 modulates gluconeogenesis and mediates glucose homeostasis under 
physiological and pathological conditions, suggesting that deeper understanding how 
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1 |  INTRODUCTION
Glucose homeostasis is of great importance for survival and 
metabolic health in general. Blood glucose levels must be 
maintained within a narrow range to avoid hypoglycemia 
during periods of fasting and hyperglycemia after calorie 
overload. Liver plays a key role in the regulation of systemic 
glucose levels because hepatic glucose production contrib-
utes to 80% of total endogenous glucose production.1 Hepatic 
glycogenolysis is mainly responsible for glucose production 
in the short-term fasting but gluconeogenesis is of much 
greater importance during prolonged fasting.2 Hepatic glu-
coneogenesis is mainly controlled by the availability of sub-
strates and the rate-limiting enzymes phosphoenolpyruvate 
carboxykinase 1 (encoded by Pck1) and glucose-6-phospha-
tase (encoded by G6pc). This process is tightly modulated 
through the actions of insulin and glucagon, which coordi-
nately respond to nutrient status. In patients with diabetes 
and other metabolic disorders, inappropriate activation of 
gluconeogenesis and development of insulin resistance ren-
der hyperglycemia.
Peroxisome proliferative activated receptor-γ co-activator 
1 (PGC1α) was originally identified in brown fat, regulat-
ing adaptive thermogenesis as a transcriptional coactivator.3 
Further investigation revealed that PGC1α can be induced 
by cyclic adenosine monophosphate (cAMP) in primary he-
patocytes and was significantly induced in the liver by fast-
ing.4 PGC1α is the master modulator of hepatic metabolism 
through regulation of gluconeogenesis, lipid catabolism, mi-
tochondrial biogenesis via interactions with many key factors, 
including forkhead transcription factor (FOXO1), hepatocyte 
nuclear factor 4α (HNF4α), and Sirtuin 1 (SIRT1).4-7 The ac-
tivity of PGC1α is closely monitored and tightly controlled at 
transcriptional and post-translational levels to accommodate 
its versatile functions in various physiological processes,8 in-
cluding arginine methylation.9
Methylation of arginine residues is a common post-transla-
tional modification and is regulated by a family of gene prod-
ucts called protein arginine methyltransferases (PRMTs).10 
PRMTs are classified as type Ⅰ (PRMT1, 2, 3, 4, 6, and 8), 
type Ⅱ (PRMT5 and 9) and type Ⅲ (PRMT7) on the basis of 
their methylation manner.11 PRMT1 is the predominant mem-
ber of the PRMT family, contributing to around 85% of pro-
tein arginine methylation in mammalian cells and tissues. It 
has been reported that PRMT1 modulates insulin signaling,12 
maintains cardiac function,13 mediates lipogenesis in the 
liver,14 and regulates thermogenesis in fat.15 Prmt1 has dif-
ferent splicing variants with distinct subcellular localization, 
substrate specificity, and enzyme activity.16 Among all these 
isoforms, PRMT1V1 and PRMT1V2 are the two main variants 
in normal human tissues.16 The difference between these two 
isoforms is that PRMT1V1 has a chromosome region main-
tenance 1/exportin1/Exp1/Xpo1 (CRM1)-dependent nuclear 
export sequence which is coded by exon 2.15,16
In this study, multiple lines of in vitro and in vivo ev-
idence generated from gain- and loss-of-function models 
strongly support the hypothesis that PRMT1, variant 2 in 
particular, plays an essential role in regulating hepatic glu-
coneogenesis via interactions with PGC1α. PRMT1V2 was 
induced in the liver of mouse models mimicking diabetes 
and other metabolic disorders where pathological hyper-
glycemia was observed. Mice with hepatocyte-specific 
Prmt1 deletion displayed less elevated blood glucose levels 
and improved glucose homeostasis when challenged with 
streptozocin or high fat diet (HFD), indicating inhibition 
of hepatic PRMT1 activity may represent therapeutic op-
portunities counteracting inappropriate gluconeogenesis in 
human diseases.
2 |  MATERIALS AND METHODS
2.1 | Reagents
Glucagon (G2044), forskolin (F6886), insulin (I5500, for in 
vitro studies), dexamethasone (D4902), fetal bovine serum 
(FBS) (F0926), cycloheximide (CHX; C4859), MG132 
(M7449), ammonium chloride (NH4Cl; A9434), and strep-
tozocin (STZ; S0130) were purchased from Sigma-Aldrich. 
Insulin (NDC 0002-8215-01, for in vivo studies) was pur-
chased from Eli Lilly. Hanks' Balanced Salt Solutions (HBSS; 
SH3058802) was purchased from Thermo Fisher Scientific. 
Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 
GlutaMAX (DMEM/F12 GlutaMAX) (10565-042), DMEM 
(11995073), DMEM-low glucose (11885084), and penicil-
lin streptomycin solution (15140122) were purchased from 
Life Technologies. Collagenase Type IV (LS004188) was 
purchased from Worthington Biochemical. Polyethylenimine 
(PEI; linear, molecular mass of 25 kDa; 23966-1) was pur-
chased from Polysciences, Inc
PRMT1 contributes to the coordinated efforts in glycemic control may ultimately pre-
sent novel therapeutic strategies that counteracts hyperglycemia in disease settings.
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2.2 | Animal studies
All the mouse studies were conducted according to the proto-
col reviewed and approved by the Institutional Animal Care 
and Use Committee at the University of Michigan. All mice 
were housed under 12-hour light/12-hour dark cycle with an 
ad libitum chow diet (5L0D; PicoLab Laboratory Rodent 
Diet) unless otherwise indicated. The C57BL/6J (000664) and 
Albumin-Cre (003574) mice were obtained from the Jackson 
Laboratory. Prmt1fl/fl mice were obtained from Dr Steven A. 
Weinman. The conditioned alleles lead to Cre-mediated dele-
tion of exon 4 and 5 of Prmt1 gene.17 Liver-specific Prmt1 KO 
mice (Alb-Cre;Prmt1fl/fl) were generated by crossing Prmt1fl/fl  
and Alb-Cre mice. For the fasting experiments, mice were 
fasted during the dark period for indicated time. Blood glu-
cose levels were measured in tail blood by using the OneTouch 
Ultra Glucometer (Lifescan). For adenovirus infusion studies, 
indicated adenoviruses were injected into anesthetized mice 
through tail vein. For STZ studies, mice were intraperitoneally 
injected with either vehicle or 100 mg per kg body weight per 
day STZ for one week. For HFD-induced obesity study, mice 
were singly housed on either a chow diet or a HFD that con-
sists of 45% of calories from fat (D12451, Research Diets) for 
indicated time. Over this period, body weights and food intake 
were measured weekly. For diet-induced nonalcoholic steato-
hepatitis (NASH) study, mice were singly housed on either a 
chow diet or Gubra Amylin NASH (GAN) diet (D09100310, 
Research Diets). Over this period, body weights and food in-
take were measured weekly. Both male and female were used 
in this study and similar results were observed in both genders.
2.3 | Quantitative real-time PCR
Total RNA was extracted from cells and tissues using TRI rea-
gent (T9424, Sigma-Aldrich) according to the manufacturer's 
instructions. cDNA was synthesized using M-MLV Reverse 
Transcriptase (28025021, Life Technologies). Quantitative 
real-time PCR (qPCR) reactions were performed with SYBR 
Green (4368708, Thermo Fisher Scientific) on a QuantStudio 
5 Real Time PCR system (Thermo Fisher Scientific). Results 
were analyzed by using the 2−ΔΔCt method and normalized to 
levels of TATA-box binding protein (Tbp). All qPCR primer 
sequences are listed in Table S1.
2.4 | Western blot
Total protein from cells and liver tissue was extracted in ice-
cold radioimmunoprecipitation assay buffer (RIPA buffer) 
(150 mM NaCl, 50 mM Tris-HCl pH 8.0, 5 mM EDTA, 0.5% 
sodium deoxycholate, 0.1% SDS, 1% NP-40) supplemented 
with protease inhibitor cocktail (Sigma-Aldrich). Protein 
concentration was measured by DC protein assay reagents (Bio-
Rad Laboratories) in SpectraMax M3 multi-mode microplate 
reader (Molecular Devices). Protein lysate was subjected to 
SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) 
membranes. After incubation with blocking buffer (5% nonfat 
milk in 1% TBS with Tween 20) for 1 hour, the membranes were 
probed with primary anti-PRMT1 (Cell Signaling Technology, 
catalog 2449S), anti-HSP90 (Cell Signaling Technology, 
catalog 4874S), anti-HA (Cell Signaling Technology, cata-
log 3724), anti-α-tubulin (Cell Signaling Technology, cata-
log 2144), anti-Adme-R (Cell Signaling Technology, catalog 
13522), anti-pAkt (Cell Signaling Technology, catalog 9271S), 
anti-Akt (Cell Signaling Technology, catalog 9272), and anti-
Histone H3 (Active motif, catalog 39763). Secondary antibody 
linked with horseradish peroxidase was diluted in 5% nonfat 
milk in 1% TBS with Tween 20 and incubated for 2 hours at 
room temperature. The blots were developed by ECL (Bio-Rad 
Laboratories, 1705061). Quantification of immunoblot analy-
ses was performed using Quantity One (Bio-Rad).
2.5 | Subcellular fractionation
Liver tissue was minced in ice-cold cytoplasm extraction 
buffer (20 mM HEPES, 1 mM EDTA, 10 mM NaCl, 2 mM 
MgCl2, 0.25% NP-40) supplemented with protease inhibitor 
cocktail (Sigma-Aldrich) whereas cells were scraped in ice-
cold cytoplasm extraction buffer. The homogenate was vor-
texed for 15 seconds followed by 5 minutes incubation at 4°C 
for 6 times. The lysate was centrifuged at 5000g at 4°C for 
5 minutes to get the supernatant containing cytoplasmic frac-
tion. The pellet after centrifugation was vortexed for 15 sec-
onds and incubated at 4°C for 10 minutes in ice-cold nuclear 
extraction buffer (20 mM HEPES, 1 mM EDTA, 420 mM 
NaCl, 2  mM MgCl2, 0.25% NP-40, 25% glycerol) supple-
mented with protease inhibitor cocktail (Sigma-Aldrich). The 
homogenate was centrifuged at 14 000g at 4°C for 5 minutes 
to get the supernatant containing nuclear fraction.
2.6 | Immunoprecipitation
Hepa 1-6 cells were infected with indicated adenoviruses or 
transiently transfected with indicated plasmids. At 48 hours 
following infection or transfection, cells were lysed with ice-
cold RIPA buffer on a shaker at 4°C for 1 hour. The lysate was 
centrifuged at 14 000g for 15 minutes at 4°C to pellet debris 
and the supernatant was transferred into a fresh Eppendorf 
tube. After quantification by DC assay, 1 mg of protein for 
each group was incubated with anti-PGC1α (Millipore, cata-
log ST1202) overnight at 4°C with rotation. Five percent of 
the lysate was saved as input. Thirty microliters of protein 
G-agarose (Santa Cruz Biotechnology, catalog sc-2002) was 
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washed with RIPA buffer 3 times and then, added into pro-
tein lysate following rotation at 4°C for 3 hours. The beads 
were pelleted by quick spin and washed with RIPA buffer 3 
times. After removing supernatant, 30 μL of sample buffer 
was added to elute the immunoprecipitated proteins followed 
by boiling at 98°C for 5 minutes. The immunoprecipitated 
protein was subjected to immunoblotting as described above.
2.7 | Tolerance tests
For pyruvate tolerance test (PTT), mice were fasted for 
16  hours and then, intraperitoneally injected with sodium 
pyruvate (1.75  g/kg). For glucose tolerance test (GTT), 
mice were fasted for 16 hours and then, intraperitoneally in-
jected with glucose (1 g/kg). The blood glucose levels were 
measured in tail blood at indicated time points by using the 
OneTouch Ultra Glucometer (Lifescan).
2.8 | Cell culture
Mouse primary hepatocytes were isolated and cultured as pre-
viously reported.15 In brief, the liver was perfused with washing 
buffer (HBSS buffer supplemented with 0.5 mM EGTA pH 7.4 
and 25 mM HEPES pH 7.4) and then, with digestion medium 
(DMEM-low glucose supplemented with 1% penicillin-strepto-
mycin, 15 mM HEPES pH 7.4, and 100 U/mL collagenase IV) 
via the inferior vena cava after the anesthesia of the mouse. After 
dispersing the cells, they were filtered by using a prechilled BD 
disposable falcon tube nylon filter. Hepatocytes were washed 
twice by using isolation medium (DMEM/F12 GlutaMAX sup-
plemented with 10% FBS, 1% penicillin-streptomycin, 1 µM 
dexamethasone, and 0.1 µM insulin) and seeded on collagen 
coated 12-well plates at 3  ×  105  cells/mL with the isolation 
medium. One hour after plating, the medium was changed to 
culture medium (DMEM-low glucose supplemented with 10% 
FBS, 1% penicillin-streptomycin, 0.1 µM dexamethasone, and 
1 nM insulin). Cells will be serum starved for 24 hours before 
treatments (such as glucagon).
Hepa 1-6 cells and HepG2 cells were obtained from 
ATCC and maintained in DMEM supplemented with 10% of 
FBS and 1% of penicillin-streptomycin. Particularly, HepG2 
cells were seeded on culture plates coated with type I rat tail 
collagen (CB354249, Fisher Scientific).
2.9 | Histology
Liver tissues were fixed in 10% formalin at 4°C overnight. 
Paraffin embedding and hematoxylin and eosin (H&E) 
staining were performed by the University of Michigan 
Comprehensive Cancer Center Research Histology and 
Immunoperoxidase Laboratory. Images were obtained by 
using LEICA DM2000.
2.10 | Adenovirus production
Adenoviruses that overexpress GFP, CRE, PGC1α,18 HA-
PRMT1V1, and HA-PRMT1V215 were generated as previ-
ously described. Adenoviruses expressing shRNA against 
Ppgargc1a6 and PRMT115 were produced as previously de-
scribed. Media were freshed 16-24 hours after infection and 
high efficiency of virus transduction that exceeded 90% was 
verified by the number of GFP-positive cells under fluores-
cence microscope.
2.11 | Luciferase reporter assays
Plasmids expressing PRMT1V1, PRMT1V2,15 PRMT1V2-
G98R,19,20 FOXO1,21 PGC1α,18 PGC1α-ΔE, PGC1α-R3K9 
and the Pck1 promoter luciferase reporter4 were described pre-
viously. Hepa 1-6 cells or HepG2 cells were seeded into 12-
well plates and transiently transfected with plasmids expressing 
PGC1α (909 ng), PGC1α-ΔE (909 ng), PGC1α-R3K (909 ng), 
or FOXO1 (909 ng) and/or PRMT1V1 (909 ng), PRMT1V2 
(909 ng) or PRMT1V2-G98R (909 ng) by using PEI method 
together with Pck1 promoter luciferase reporter construct 
(90.0 ng) and Renilla luciferase reporter construct (10 ng) un-
less otherwise specified. Cells were lysed 48 hours after trans-
fection. Luciferase activity was measured by a luciferase assay 
kit (PR-E1941, Promega) according to the manufacturer's rec-
ommendations by using a Perkin Elmer Enspire Model 2300 
Multilabel Microplate Reader (PerkinElmer). Firefly luciferase 
activity was normalized to Renilla luciferase activity.
2.12 | Statistics
Data are presented as mean  ±  SEM. Two-tailed unpaired 
Student's t test was used for comparison of two genotypes 
or treatments. One-way ANOVA or two-way ANOVA was 
performed to compare 3 or more groups, as indicated in the 
figure legends. All the statistical analyses were performed 
using SPSS (IBM).
3 |  RESULTS
3.1 | Hepatic Prmt1 deficiency renders 
impaired gluconeogenesis in the liver
To investigate the role of PRMT1 in regulating hepatic glu-
cose metabolism, we first examined wild-type (WT) mice 
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subjected to fasting for 16  hours. As expected, mice in the 
fasted state had lower body weights and reduced blood glucose 
levels compared to mice with free access to food (Figure 1A). 
qPCR analyses revealed that expression levels of key glucone-
ogenic genes, including Pck1, G6pc, Ppargc1a, and CCAAT/
enhancer binding protein beta (Cebpb), were elevated in the 
liver isolated from mice after overnight fasting compared to 
those of fed controls (Figure 1A). It is of great interest that 
fasting significantly increased global asymmetric arginine 
dimethylation with increased PRMT1 expression on the pro-
tein level but not transcriptionally in the liver (Figure 1A,B). 
To mechanistically investigate the posttranscriptional induc-
tion of PRMT1 expression in the liver in the fasting state, a 
cycloheximide chase experiment was performed to reveal 
whether this is due to changes in the rate of protein degra-
dation. Treatment with gluconeogenic stimulating hormone, 
glucagon, dramatically extended the half-life of PRMT1 from 
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treated with cycloheximide, a commonly used protein syn-
thesis inhibitor22 (Figure 1C). Further investigation revealed 
that increased PRMT1 protein accumulation was observed in 
the primary hepatocytes treated with a proteasome inhibitor 
MG13222 but not NH4Cl, a lysosome inhibitor,
23 suggesting 
that proteasomal pathways may be involved (Figure S1A,B).
In addition to being stimulated by glucagon after pro-
longed fasting, gluconeogenesis is also governed by the 
suppressive effects of insulin postprandially. Reduced sup-
pression of hepatic glucose production rendered by insulin 
resistance is one of key causes for hyperglycemia observed 
in type 2 diabetes.24 Therefore, we next investigated whether 
insulin is also involved in the regulation of hepatic PRMT1. 
WT mice were subjected to fasting for 16  hours, followed 
by intraperitoneal injection with insulin. Insulin treatment 
did not lead to changes in PRMT1 mRNA or protein lev-
els (Figure S1C,D). Similarly, no changes were observed in 
PRMT1 mRNA and protein in vitro in primary hepatocytes 
treated with insulin (Figure S1E,F), indicating minimal regu-
latory effects through insulin in this context.
To determine whether Prmt1 is required in the hepatic 
gluconeogenesis, we generated liver-specific Prmt1 KO mice 
(Alb-Cre;Prmt1fl/fl) by crossing Prmt1fl/fl mice with Albumin-
Cre mice. Hepatocyte-specific deletion of Prmt1 did not 
cause any gross abnormality under the basal conditions. Alb-
Cre;Prmt1fl/fl mice showed no differences in body weight and 
morphological architecture in the liver compared with Prmt1fl/fl 
controls (Figure  1D,E). Prmt1 deletion was confirmed by 
qPCR in the liver and no deletion was detected in other tissues 
that express Prmt1 (Figure 1F). Additionally, no other Prmts 
were induced to compensate for the loss of Prmt1 expression 
in the liver (Figure S2A). Western blot analyses further con-
firmed PRMT1 deletion in the liver with significantly reduced 
global asymmetric arginine dimethylation (Figure  1G), con-
sistent with the notion that PRMT1 plays a predominant role 
in the liver among all the PRMTs.25 Alb-Cre;Prmt1fl/fl mice 
exhibited no changes in gluconeogenic gene expression in the 
liver under the fed state (Figure 1H). It has previously been re-
ported that deletion of Prmt1 in the liver may influence cellu-
lar response to stresses rendered by environmental insults such 
as alcohol.26 Decreased expression of oxidative stress response 
genes (Sod1 and Sod2), increased expression of proliferation 
markers (Cyclin B1 and c-Myc) and comparable expression of 
genes regulating inflammation, cell death and fibrosis were 
observed in the liver of Alb-Cre;Prmt1fl/fl mice compared to 
that in the Prmt1fl/fl controls under basal conditions (ad lib) 
(Figure S2B), consistent with previous observations.26 After 
overnight fasting, Alb-Cre;Prmt1fl/fl mice had lower blood glu-
cose levels and decreased expression of gluconeogenic genes 
compared to littermate control mice (Figure 1I,J). Yet, fasting 
did not result in changes in the expression pattern of the stress 
response genes between the two genotypes (Figure S2C), sug-
gesting the blunted gluconeogenesis in the Prmt1-deleted liver 
after fasting was mediated through a specific regulatory sig-
naling pathway rather than due to global defects or organ fail-
ure. PTT revealed that hepatic gluconeogenesis was impaired 
after the deletion of Prmt1 (Figure 1K). It has been reported 
that global haploinsufficiency of Prmt1 resulted in impaired 
gluconeogenesis and significant reduction of PRMT1 protein 
levels in the liver.27 However, no differences in the expression 
of gluconeogenic genes were observed in the liver of Alb-
Cre;Prmt1fl/+ mice compared to those of Prmt1fl/fl mice after 
overnight fasting. Furthermore, western blot analyses revealed 
that PRMT1 protein levels were comparable in the liver from 
Alb-Cre;Prmt1fl/+ mice to those of littermate Prmt1fl/fl mice 
controls (Figure S2D,E).
Similar to what was observed in the Alb-Cre;Prmt1fl/fl 
mice where Prmt1 was deleted developmentally, acute he-
patic deletion of Prmt1 mediated by adenoviral expression 
of recombinase Cre led to lower fasting blood glucose, less 
induced hepatic gluconeogenic gene expression after fasting 
and less glucose production upon pyruvate challenges with 
F I G U R E  1  Loss of Prmt1 reduces gluconeogenic capacity in the liver. A, Body weights (left; n = 7 for ad lib, n = 6 for fasted), blood glucose 
levels (middle; n = 7/group), and qPCR analyses (right; n = 7/group) of Prmt1 and gluconeogenic marker mRNA levels in the liver of wild-
type (WT) mice under ad libitum-fed and 16 hour-fasted conditions. B, Immunoblot analyses of PRMT1 and asymmetric-dimethylated arginine 
(Adme-R) in the liver of mice described in (A) (n = 3/group). HSP90 was used as a loading control. C, Immunoblot (left) and quantification (right) 
analyses of PRMT1 in the primary hepatocytes isolated from WT mice and treated with 100 μg/mL cycloheximide (CHX) for indicated time after 
pretreatment with vehicle (Ctrl) or 200 nM glucagon for 3 hours. α-tubulin was used as a loading control. D, Body weights of Prmt1fl/fl and Alb-
Cre;Prmt1fl/fl mice under basal conditions (chow diet, fed state, n = 6/group). E, H&E-stained images of the liver in mice described in (D) (scale 
bar, 100 μm). F, qPCR analyses of Prmt1 mRNA levels across tissues from Prmt1fl/fl and Alb-Cre;Prmt1fl/fl mice (n = 4 for Prmt1fl/fl,  
n = 3 for Alb-Cre;Prmt1fl/fl). G, Immunoblot analyses of PRMT1 and Adme-R in the liver from mice described in (D) (n = 2/group). HSP90 was 
used as a loading control. H, qPCR analyses of Prmt1 and gluconeogenic marker mRNA levels in Prmt1fl/fl and Alb-Cre;Prmt1fl/fl mice under 
basal conditions (chow diet; fed state; n = 8 for Prmt1fl/fl, n = 6 for Alb-Cre;Prmt1fl/fl). I, Blood glucose levels of 16 hour-fasted Prmt1fl/fl and 
Alb-Cre;Prmt1fl/fl mice (n = 6 for Prmt1fl/fl, n = 5 for Alb-Cre;Prmt1fl/fl). J, qPCR analyses of Prmt1 and gluconeogenic marker mRNA levels 
in the liver of mice described in (I) (n = 4 for Prmt1fl/fl, n = 6 for Alb-Cre;Prmt1fl/fl). K, PTT in 16 hour-fasted mice described in (I) (n = 6 for 
Prmt1fl/fl, n = 5 for Alb-Cre;Prmt1fl/fl). AUC, area under the curve. L, qPCR analyses of PRMT1 and GFP mRNA levels in HepG2 cells infected 
with indicated adenoviruses (n = 6/group). M, qPCR analyses of gluconeogenic marker mRNA levels in HepG2 cells infected with indicated 
adenoviruses and stimulated with 1 mM glucagon plus 10 μM forskolin or vehicle (Ctrl) for 24 hours (n = 6/group). Data are presented as 
mean ± SEM. *P < .05; **P < .01; ***P < .001. n.s., not significant. Two-tailed Student's t test (A, D, F, H-L) or two-way ANOVA (M)
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no gross differences and morphological changes in the liver 
under ad lib conditions (Figure S3A-H, and data not shown). 
The cell-autonomous regulation of hepatic gluconeogenesis 
through PRMT1 was further confirmed by the observation 
that Prmt1 deletion significantly blunted the glucagon-me-
diated induction of Pck1, G6pc, Ppargc1a, and Cebpb in the 
primary hepatocytes (Figure S3I,J).
We next investigated whether the effects of PRMT1 on 
gluconeogenesis are conserved in human using a loss-of-func-
tion model (Figure 1L). Treatment of glucagon plus forskolin 
(increasing intracellular cAMP levels) activated the gluco-
neogenic program in HepG2 cells, a commonly used human 
hepatoma cell line (Figure  1M), in agreement with previ-
ous results.28 However, knockdown of PRMT1 significantly 
ablated the response of HepG2 cells to glucagon plus forskolin 
stimulation (Figure 1M), confirming that the role of PRMT1 
in glucose regulation is conserved in human liver cells.
3.2 | PRMT1V2 plays a dominant role in 
activating the hepatic gluconeogenic program
Among the various isoforms of PRMT1, which one(s) may 
contribute primarily to this critical role in gluconeogenic reg-
ulation is completely unknown. We first investigated the rel-
ative expression of Prmt1v1 and Prmt1v2 in the liver, the two 
dominant isoforms in humans that differs from each other by 
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We found that the expression of Prmt1v2 was higher than 
Prmt1v1 in the liver from WT mice (Figure S4A). A similar 
expression pattern of Prmt1v1 and Prmt1v2 was observed in 
primary hepatocytes isolated from WT mice, Hepa 1-6 cells (a 
murine hepatoma cell line) and HepG2 cells (Figure S4B-D). 
Interestingly, western blot analyses of subcellular fractiona-
tions revealed that PRMT1 expression within the nucleus 
was increased in the fasted liver while cytosolic PRMT1 re-
mained unchanged (Figure 2B), suggesting that PRMT1V2 
might be the isoform that activates hepatic gluconeogenesis.
To further explore the role of these two isoforms in the he-
patic glucose production, gain-of-function experiments were 
carried out with adenoviruses that overexpress PRMT1V1 
and PRMT1V2, which displayed subcellular expression pat-
tern as expected (Figures 2C-G, S4E-G). Overexpression of 
PRMT1V2 significantly induced the expression of glucone-
ogenic genes in the mouse primary hepatocytes whereas lit-
tle effects were observed in cells overexpressing PRMT1V1 
(Figure 2D,F).
To test this effect in vivo, we ectopically expressed 
PRMT1V1 and PRMT1V2 in the mice with hepatic deletion 
of endogenous Prmt1 (Figure 2H-J). Mice injected with ad-
enovirus overexpressing PRMT1V2 displayed higher blood 
glucose levels after fasting for 6 and 16 hours (Figure 2K). 
However, there was no difference in fasted blood glucose 
levels between mice injected with adenovirus overexpressing 
GFP and PRMT1V1 (Figure 2K). In addition, gluconeogenic 
genes, including Pck1, G6pc, Ppargc1a, and Cebpb, were 
significantly induced in mice with PRMT1V2 overexpres-
sion, but not PRMT1V1, after 16-hour fasting (Figure 2L). 
PTT results demonstrated that hepatic gluconeogenic capac-
ity was augmented in mice with PRMT1V2 overexpression 
but remained unchanged in mice with PRMT1V1 over-
expression (Figure  2M). Similar to what was observed in 
murine primary hepatocytes, overexpression of PRMT1V1 
did not affect the gluconeogenic program in HepG2 cells 
(Figure 2N,O). On the contrary, PRMT1V2 overexpression 
significantly increased the expression of gluconeogenic 
genes (Figure 2P,Q). These results suggest that PRMT1V2 
plays a major role in regulating hepatic gluconeogenesis.
3.3 | PRMT1V2 stimulates hepatic 
gluconeogenesis via PGC1α
PGC1α is a transcriptional coactivator that regulates multi-
ple physiological functions in metabolism, including adap-
tive thermogenesis and gluconeogenesis.3,4,29 It has been 
reported that the arginine residues of PGC1α could be meth-
ylated by PRMT1 and its coactivator activity was increased 
after methylation.9 Consistent with previous reports,4 over-
expression of PGC1α significantly induced the expression 
of gluconeogenic genes (Figure 3A). Co-overexpression of 
PRMT1V2 but not PRMT1V1 with PGC1α can lead to fur-
ther increase in expression levels of gluconeogenic genes in 
primary hepatocytes, likely through activated PGC1α that 
was methylated primarily by nucleus-located PRMT1V2 
but not PRMT1V1 in the cytosol (Figure 3B,C). This glu-
coneogenic effect of PRMT1V2 was also observed in ex-
periments testing Pck1 promoter activity in Hepa 1-6 cells 
(Figure 3D,E). In Hepa 1-6 cells, knockdown of Ppargc1a 
reduced Pck1-luciferase activity (Figure 3F-H). Transient 
transfection of PRMT1V2 increased Pck1-luciferase activ-
ity while there were no effects observed in cells transfected 
F I G U R E  2  PRMT1V2 (P1V2) is primarily responsible for the modulation of hepatic gluconeogenesis. A, Schematic of PRMT1V1 (P1V1) 
and P1V2 transcript structure. B, Immunoblot analyses of PRMT1 in purified nuclear and cytoplasmic fractions of liver from wild-type (WT) mice 
under ad libitum-fed and 16 hour-fasted conditions. Histone H3 (H3) and α-tubulin served as nuclear and cytoplasmic markers, respectively. C, 
Immunoblot analyses of PRMT1 in purified nuclear and cytoplasmic fractions of Hepa 1-6 cells infected with indicated adenoviruses. Histone H3 
(H3) and α-tubulin served as nuclear and cytoplasmic markers, respectively. D, qPCR analyses of P1V1 and gluconeogenic marker mRNA levels 
after infection with indicated adenoviruses in primary hepatocytes isolated from WT mice (n = 4/group). E, Immunoblot analyses of HA-P1V1 
with anti-HA antibody in primary hepatocytes described in (D) (n = 2/group). HSP90 was used as a loading control. F, qPCR analyses of P1V2 
and gluconeogenic marker mRNA levels after infection with indicated adenoviruses in primary hepatocytes isolated from WT mice (n = 4/group). 
G, Immunoblot analyses of HA-P1V2 with anti-HA antibody in primary hepatocytes described in (F) (n = 2/group). HSP90 was used as a loading 
control. H, Schematic of the experiment. Prmt1fl/fl mice were injected with indicated adenovirus through tail vein for CRE-mediated deletion. 
Seven days after first injection, the mice were injected with indicated adenoviruses through tail vein for gain-of-function. I, qPCR analyses of P1V1 
and P1V2 mRNA levels in the liver of 16 hour-fasted mice described in (H) (n = 4 for Ad-GFP and Ad-P1V2, n = 3 for Ad-P1V1). J, Immunoblot 
analyses of PRMT1 in the liver from mice described in (H) (n = 2/group). HSP90 was used as a loading control. K, Blood glucose levels in 6- or 
16 hour-fasted mice described in (H) (n = 4 for Ad-GFP and Ad-P1V2, n = 3 for Ad-P1V1). L, qPCR analyses of gluconeogenic markers and 
GFP mRNA levels in 16 hour-fasted mice described in (H) (n = 4 for Ad-GFP and Ad-P1V2, n = 3 for Ad-P1V1). M, PTT in 16 hour-fasted mice 
described in (H) (n = 4 for Ad-GFP and Ad-P1V2, n = 3 for Ad-P1V1). AUC, area under the curve. N, qPCR analyses of P1V1 and gluconeogenic 
marker mRNA levels in HepG2 cells infected with indicated adenoviruses (n = 4/group). O, Immunoblot analyses of HA-P1V1 with anti-HA 
antibody in HepG2 cells described in (N) (n = 2/group). HSP90 was used as a loading control. P, qPCR analyses of P1V2 and gluconeogenic 
marker mRNA levels in HepG2 cells infected with indicated adenoviruses (n = 4/group). Q, Immunoblot analyses of HA-P1V2 with anti-HA 
antibody in HepG2 cells described in (P) (n = 2/group). HSP90 was used as a loading control. Data are presented as mean ± SEM. *P < .05; 
**P < .01; ***P < .001. n.s., not significant. Two-tailed Student's t test (D, F, N, P) or one-way ANOVA (I, K-M)
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F I G U R E  3  PRMT1V2 activates hepatic gluconeogenesis through PGC1α. A, qPCR analyses of Ppargc1a and gluconeogenic marker mRNA 
levels in primary hepatocytes isolated from wild-type (WT) mice and infected with indicated adenoviruses (n = 4/group). B, qPCR analyses of 
Ppargc1a, P1V1, P1V2, and gluconeogenic marker mRNA levels in primary hepatocytes isolated from WT mice and infected with indicated 
adenoviruses (n = 4/group). C, Analyses of asymmetric dimethylation of PGC1α. Hepa 1-6 cells were infected with indicated adenoviruses. Lysates 
were immunoprecipitated with an anti-PGC1α antibody. Both input and immunoprecipitates were analyzed by immunoblotting as indicated. D, 
E, Pck1 promoter activity in Hepa 1-6 cells transiently transfected with indicated vectors (n = 4/group). F, qPCR analyses of Ppargc1a mRNA 
levels in Hepa 1-6 cells infected with indicated adenoviruses (n = 6/group). G, H, Pck1 promoter activity in Hepa 1-6 cells infected with indicated 
adenoviruses and then, transiently transfected with indicated vectors (n = 6/group). I, Alb-Cre;Prmt1fl/fl mice were first injected with the adenovirus 
encoding a shRNA specific to Ppargc1a through tail vein. Three days after the first injection, the mice were injected with indicated adenoviruses 
through tail vein for gain-of-function. Blood glucose levels of these mice after 16 hour fasting (n = 3 for Ad-GFP, n = 4 for Ad-P1V1 and Ad-
P1V2). J, qPCR analyses of Ppargc1a, P1V1, P1V2, and gluconeogenic marker mRNA levels in the liver of 16 hour-fasted mice described in (I) 
(n = 3 for Ad-GFP, n = 4 for Ad-P1V1 and Ad-P1V2). K, PTT in 16 hour-fasted mice described in (I) (n = 3 for Ad-GFP, n = 4 for Ad-P1V1 and 
Ad-P1V2). AUC, area under the curve. L, qPCR analyses of PPARGC1A and gluconeogenic marker mRNA levels in HepG2 cells infected with 
indicated adenoviruses (n = 4/group). M, qPCR analyses of PPARGC1A, P1V1, P1V2, and gluconeogenic marker mRNA levels in HepG2 cells 
infected with indicated adenoviruses (n = 4/group). N, O, Pck1 promoter activity in HepG2 cells transiently transfected with indicated vectors 
(n = 4/group). Data are presented as mean ± SEM. *P < .05; **P < .01; ***P < .001. n.s., not significant. Two-tailed Student's t test (A, D, F, L, 
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with PRMT1V1 (Figure  3G,H). Notably, knockdown of 
Ppargc1a completely abolished the stimulatory effects of 
PRMT1V2 (Figure 3H). This drastic effects of PGC1α on 
PRMT1V2 function in the hepatic gluconeogenic regula-
tion were further revealed when PRMT1V1 and PRMT1V2 
were individually re-introduced back in Alb-Cre;Prmt1fl/fl 
mice after knockdown of Ppargc1a (Figure 3I-K). Elevated 
fasting blood glucose levels, induced gluconeogenic gene 
expression and compromised pyruvate tolerance observed 
previously with PRMT1V2 overexpression were com-
pletely blunted in the absence of PGC1α (Figure  3I-K). 
Similar results were observed in vitro in the primary hepat-
ocytes demonstrating a likely cell-autonomous mechanism 
(Figure  S5A,B). Conversely, even though injection with 
the adenovirus encoding an shRNA specific to Ppargc1a 
decreased the gluconeogenic capacity as expected in the 
Prmt1fl/fl mice, knockdown of Ppargc1a did not render 
further reduction in gluconeogenesis in Alb-Cre;Prmt1fl/fl 
mice, demonstrating the physiological significance of this 
PGC1α and PRMT1 interaction in vivo (Figure S5C-E).
It has been reported that PRMT1 may regulate glucose 
production through FOXO1, a transcription factor known to 
activate gluconeogenesis in the liver.27,30 But which isoform 
of PRMT1 may be involved in this process has not been in-
vestigated. In contrast to the dominant effects of PRMT1V2 
when working with PGC1α, both PRMT1V1 and PRMT1V2 
can further increase Pck1-luciferase activity when co-overex-
pressed with FOXO1 (Figure S6A,B). This coactivation be-
tween PRMT1 and FOXO1 remained functional in the cells 
infected with an adenovirus encoding a shRNA specific to 
Ppargc1a (Figure S6C,D), suggesting that PRMT1 may reg-
ulate hepatic gluconeogenesis with different partners through 
various mechanisms.
We next explored whether PRMT1V2 functions with 
PGC1α in hepatic gluconeogenic regulation in human liver 
cells. Similar to what we observed in murine hepatocytes, 
co-overexpression of PRMT1V2 and PGC1α further in-
creased gluconeogenic gene expression and Pck1 promoter 
activity compared with those observed in cells only ectopi-
cally overexpressing PGC1α, whereas little effects were ob-
served with PRMT1V1 (Figure 3L-O).
Further mechanistic investigation was carried out to test 
whether PRMT1V2 enhances PGC1α activity through ar-
ginine methylation. In contrast to what was observed with 
the wild-type PRMT1V2, which increased Pck1-luciferase 
activity when co-overexpressed with PGC1α, PRMT1V2-
G98R, a catalytically inactive mutant (Figure 4A,B),19,20 did 
not show any synergistic effects with PGC1α mediating Pck1 
promoter activation (Figure  4C). It has been proposed that 
the potential methylation sites of PRMT1 on PGC1α, argi-
nine residues 665, 667, and 669, locate within the C-terminal 
E region.9 Even though when expressed alone, either a mu-
tant PGC1α-ΔE without E region or a mutant PGC1α-R3K 
consisting of conversion of arginine residues 665, 667, and 
669 to lysine can increase Pck1-luciferase activity, neither 
mutant demonstrated coactivation effects when co-expressed 
with PRMT1V2 (Figure  4D-H). These results collectively 
support the hypothesis that PRMT1V2 mediates PGC1α 
function primarily through arginine methylation.
Our results demonstrated that PRMT1, variant 2 in partic-
ular, modulated hepatic gluconeogenesis via PGC1α. We next 
tested, as the master regulator of gluconeogenesis, whether 
PGC1α regulates PRMT1 expression in hepatocytes. PGC1α 
overexpression in HepG2 cells did not lead to changes in 
PRMT1 mRNA levels (Figure  4I), whereas increased pro-
tein levels of PRMT1 were detected in cells with adenovirus 
overexpressing PGC1α (Figure 4J). It has been reported that 
PRMT1 protein can be stabilized through downregulation of 
p300 (EP300) and Sirtuin 1 (Sirt1).22 Indeed, overexpression 
of PGC1α led to decreased expression of EP300 and SIRT1 in 
HepG2 cells (Figure 4K). Furthermore, glucagon treatments 
no longer stabilized PRMT1 in the hepatocytes in the absence 
of PGC1α (Figure 4L). These results collectively suggest that 
as a part of the machinery of glucose control in the liver, 
PRMT1 itself is regulated by PGC1α, which forms a feed-
back regulatory loop.
3.4 | Liver-specific Prmt1 deficiency 
counteracts diabetic hyperglycemia
Excessive hepatic gluconeogenesis and loss of glycemic con-
trol is one of the characteristics of diabetes and metabolic 
syndrome.1,31,32 Whether PRMT1 modulates pathologi-
cal hepatic glucose production in diabetes may be of great 
clinical relevance. Streptozocin (STZ) is widely used to kill 
insulin-producing beta cells, causes acute glucotoxicity ef-
fects in vivo and induces type 1 diabetes in mice.33 Mice in-
jected with STZ displayed higher fed blood glucose levels 
when compared with mice injected with vehicle (Figure 5A). 
In this type 1 diabetes mouse model, Prmt1 was markedly 
increased along with the induction of gluconeogenic genes 
(Figure  5A,B). It is of note that Prmt1v1 was not changed 
but Prmt1v2 was significantly induced in the liver of mice 
injected with STZ (Figure  5A). These results suggest that 
PRMT1 is involved in the inappropriate hepatic glucose pro-
duction in diabetes.
To investigate how the absence of Prmt1 may affect 
pathological hepatic gluconeogenesis, we injected Alb-
Cre;Prmt1fl/fl and Prmt1fl/fl control mice with STZ. After 
STZ injection, liver-specific deletion of Prmt1 resulted in 
less elevated blood glucose levels and less induced glucone-
ogenic gene expression in the liver in the fed state compared 
to STZ-injected Prmt1fl/fl control mice (Figure 5C,D). GTT 
revealed that Alb-Cre;Prmt1fl/fl mice had better control of 
glycemia after STZ injection (Figure  5E). These results 
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indicate that hepatic deletion of Prmt1 may protect against 
pathological hepatic gluconeogenesis in type 1 diabetes.
In addition to type 1 diabetes, hepatic regulation of glu-
cose constitutes a very important aspect of liver dysfunction in 
various metabolic disorders. Chronic HFD feeding promotes 
obesity and insulin resistance and has been used as a model to 
induce both type 2 diabetes and nonalcoholic fatty liver disease 
(NAFLD) in mice.34 Mice on HFD had higher body weights 
and elevated fasting blood glucose levels compared with mice 
on chow diet as expected (Figure 5F). qPCR analyses showed 
F I G U R E  4  PRMT1V2 activates PGC1α by asymmetric dimethylation. A, Schematic of PRMT1V2-G98R mutant. B, Analyses of asymmetric 
dimethylation of PGC1α. Hepa 1-6 cells were transiently transfected with indicated plasmids. Lysates were immunoprecipitated with an anti-
PGC1α antibody. Both input and immunoprecipitates were analyzed by immunoblotting as indicated. C, Pck1 promoter activity in Hepa 1-6 cells 
transiently transfected with indicated vectors (n = 4/group). D, Schematic of PGC1α mutants. WT, wild-type; AD, activation domain; RS, serine/
arginine-rich region; RRM: RNA recognition motif. E-H, Pck1 promoter activity in Hepa 1-6 cells transiently transfected with indicated vectors 
(n = 4/group). I, qPCR analyses of PRMT1 mRNA levels in HepG2 cells infected with indicated adenoviruses (n = 4/group). J, Immunoblot 
analyses of PRMT1 in HepG2 cells described in (I) (n = 3/group). HSP90 was used as a loading control. K, qPCR analyses of EP300 and SIRT1 in 
HepG2 cells described in (I) (n = 4/group). L, Immunoblot (left) and quantification (right) analyses of PRMT1 in primary hepatocytes isolated from 
wild-type mice after injection with indicated adenovirus and treated with 100 μg/mL cycloheximide (CHX) for indicated time after pretreatment 
with vehicle (Ctrl) or 200 nM glucagon for 3 hours. α-tubulin was used as a loading control. Data are presented as mean ± SEM. ***P < .001. n.s., 
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F I G U R E  5  Hepatocyte-specific Prmt1 deletion ameliorates diabetic hyperglycemia. A, Blood glucose levels (left) and qPCR analyses 
of Prmt1 and gluconeogenic marker (middle) and two different Prmt1 variants mRNA levels (right) in the liver from wild-type (WT) mice 
intraperitoneally injected with vehicle (Ctrl) or 100 mg/kg streptozocin (STZ) daily for one week (n = 5 for Ctrl, n = 4 for STZ). B, Immunoblot 
analyses of PRMT1 in the liver of mice described in (A) (n = 3/group). HSP90 was used as a loading control. C, Blood glucose levels of Prmt1fl/fl  
and Alb-Cre;Prmt1fl/fl mice in the fed state after daily intraperitoneal injection with 100 mg/kg STZ for one week (n = 5 for Prmt1fl/fl, n = 4 for 
Alb-Cre;Prmt1fl/fl). D, qPCR analyses of Prmt1 and gluconeogenic marker mRNA levels in the liver of mice in the fed state described in (C) (n = 5 
for Prmt1fl/fl, n = 4 for Alb-Cre;Prmt1fl/fl). E, GTT in 16 hour-fasted mice described in (C) (n = 5 for Prmt1fl/fl, n = 4 for Alb-Cre;Prmt1fl/fl).  
AUC, area under the curve. F, Body weight (left) and 16 hour-fasted blood glucose levels (right) in WT mice on chow diet or high fat diet (HFD) 
for 12 weeks (n = 4 for Chow, n = 8 for HFD). G, qPCR analyses of Prmt1 and gluconeogenic marker (left) and two different Prmt1 variants 
(right) mRNA levels in the liver from mice described in (F) (n = 5 for Chow, n = 8 for HFD). H, Immunoblot analyses of PRMT1 in the liver 
of mice described in (F) (n = 3/group). HSP90 was used as a loading control. I, Changes in body weights of Prmt1fl/fl and Alb-Cre;Prmt1fl/fl 
mice upon HFD (n = 5 for Prmt1fl/fl, n = 8 for Alb-Cre;Prmt1fl/fl). J, Liver weight of Prmt1fl/fl and Alb-Cre;Prmt1fl/fl mice after 8 weeks on HFD 
(n = 5 for Prmt1fl/fl, n = 8 for Alb-Cre;Prmt1fl/fl). K, Blood glucose levels in 6 hour-fasted mice described in (J) (n = 5 for Prmt1fl/fl, n = 8 for 
Alb-Cre;Prmt1fl/fl). L, qPCR analyses of Prmt1 and gluconeogenic marker mRNA levels in the liver of 6 hour-fasted mice described in (J) (n = 4/
group). M, GTT in 16 hour-fasted mice described in (J) (n = 5 for Prmt1fl/fl, n = 8 for Alb-Cre;Prmt1fl/fl). AUC, area under the curve. Data are 
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that Prmt1 was significantly induced in the liver by HFD feed-
ing, accompanied by the activation of gluconeogenic genes, in-
cluding Pck1, G6pc, and Cebpb (Figure 5G,H). In particular, 
Prmt1v2 was significantly increased in the liver from mice on 
HFD while there was no difference in the expression of Prmt1v1 
between mice on chow diet and HFD (Figure 5G).
Similar to what was observed in STZ-induced type 1 di-
abetes model, when challenged with HFD feeding, hepatic 
deletion of Prmt1 provided protection against hyperglyce-
mia in this type 2 diabetes model. Upon HFD feeding, Alb-
Cre;Prmt1fl/fl mice showed lower body weight gain and less 
liver tissue mass than those of the littermate control animals 
without differences in food intake (Figure 5I,J, S7A). After 
fasting, blood glucose was lower and gluconeogenic genes 
were less induced in the liver in Alb-Cre;Prmt1fl/fl than those 
of controls (Figure 5K,L). Alb-Cre;Prmt1fl/fl mice on HFD 
showed less impaired glucose tolerance compared to litter-
mate control while these two genotypes showed comparable 
glycemia control on chow diet (Figure 5M, S7B). Together, 
these data indicate that inhibiting hepatic PRMT1 activity 
may protect against inappropriate glucose production due to 
insulin resistance.
In comparison to standard HFD, so called western diets, 
which contains high-fat, high fructose and high cholesterol, 
are more widely used as a more specific model for fatty 
liver study, which better mimics fast food style diets.34 It is 
of great interest to observe that Prmt1, particularly Prmt1v2 
was increased in the livers of mice challenged with western 
diet and loss of hepatic Prmt1 protected mice from metabolic 
dysfunction caused by a western diet (Figure S8). These data 
indicate that PRMT1 may be involved in hepatic regulation in 
a broad spectrum of metabolic disorders.
4 |  DISCUSSION
Our study revealed that Prmt1 deficiency results in impaired 
gluconeogenesis in the liver during fasting. PRMT1V2 is 
the isoform that is primarily responsible for glucose regula-
tion through interactions with PGC1α and this mechanism is 
conserved in human hepatocytes. Hepatic deletion of Prmt1 
protects against inappropriate activation of gluconeogenesis 
in metabolic disorder, such as diabetes.
The expression profiling of different isoforms of Prmt1 
showed that Prmt1v2 was expressed at a higher level than 
Prmt1v1 in mouse and human hepatocytes. Functional analy-
ses revealed that PRMT1V2 activated the gluconeogenic pro-
gram in the hepatocytes and augmented glucose production 
in vivo, while there were no effects of PRMT1V1. The differ-
ence between Prmt1v1 and Prmt1v2 is that there is a nuclear 
export sequence in Prmt1v1 which makes PRMT1V1 ex-
ported to the cytoplasm and PRMT1V2 exist in the nucleus16 
(Figure  2A,C), indicating that PRMT1V2 may activate 
gluconeogenesis through modulating transcription, likely 
through controlling methylation of transcriptional regulators, 
such as PGC1α (Figures 3C, 4A-H).
A previous study has implicated that PRMT1 may be 
involved in glucose control through a FOXO1-dependent 
mechanism.27 However, the differential regulation via differ-
ent isoforms of PRMT1 was not investigated. It is also of note 
that the levels of PRMT1 protein were significantly reduced 
in the Prmt1+/− mice in this previous study,27 whereas similar 
protein levels of PRMT1 were detected in the liver of Alb-
Cre;Prmt1fl/+ mice compared to that in the control Prmt1fl/fl  
mice in our study. It is conceivable that systemic haploin-
sufficiency of PRMT1 may lead to secondary influence on 
liver function and complicate the interpretation of the phe-
notype observed in Prmt1+/− mice. We observed that, when 
co-overexpressed, both PRMT1V1 and PRMT1V2 works 
with FOXO1 to activates Pck1 promoter activity regardless 
the presence or absence of PGC1α, indicating that PRMT1 
closely interacts with key modulators of liver glucose control 
through multiple mechanisms.
Our study revealed a feedback regulation between 
PRMT1V2 and PGC1α in hepatocytes. PGC1α was strongly 
induced in the liver of mice in the fasted state and overexpres-
sion of PGC1α through adenoviral delivery stimulated hepatic 
gluconeogenesis.4 Deletion of Ppargc1a reduced the hepatic 
glucose production in the fasted mice.29 It has been reported 
that PGC1α is induced in STZ-induced and db/db diabetic 
mice.4,35 Knockdown of Ppargc1a could reduce hepatic glu-
coneogenesis in the diabetes mouse model.35 Intriguingly, it is 
also well documented that PPARGC1A expression is reduced 
in the liver of humans with diabetes and NAFLD.36-38 The pre-
cise modulation of PGC1α activity in the liver is critical in 
systemic glucose control.39 Our study suggests that PRMT1V2 
represents another key module in this complex network that 
acutely senses nutritional and hormonal cues and consists of 
many regulators, including PGC1α and FOXO1.
Protein arginine methylation is an important posttran-
scriptional modification for protein function.40 It has been 
reported that multiple cellular processes are regulated by 
arginine methylation, including RNA processing, signaling 
transduction, and transcriptional regulation.40 PRMT1 is the 
key member of the PRMT family, which is responsible for 
most of the asymmetric dimethylation. PRMT1 is expressed 
in various tissues.25 It has been reported that PRMT1 is in-
volved in a variety of biological processes, including tran-
scriptional control, DNA repair, mRNA splicing, and signal 
transduction.10 PRMT1 was further shown to play a role in 
cancer progression41 and thermogenesis activation in fat.15 
Previous studies indicated that PRMT1 regulates lipogen-
esis in hepatic steatosis and alcohol-induced liver dysfunc-
tion.14,26,42-44 Despite of the fact that pleiotropic effects 
of PRMT1 have been investigated in various tissues, the 
unique discovery of the current study lies in the specific and 
14876 |   MA et Al.
fine-tuned regulation mediated by this interaction between 
PGC1α and PRMT1V2. This isoform specific coactivation 
is regulated primarily by nucleus localized PRMT1V2. On 
the one hand, methylation-resistant form of PGC1α can still 
regulate gluconeogenesis (Figure 4E,G), suggesting, not sur-
prisingly, this master regulator of liver function can be mod-
ulated by other factors besides PRMT1. Yet, the synergistic 
effects between PGC1α and PRMT1V2 are almost com-
pletely absent when arginine methylation is blocked. Either 
loss of catalytical ability of PRMT1V2 or mutations in the 
potential arginine methylation sites in PGC1α abolished the 
synergistic effects of this PGC1α and PRMT1 interaction. 
PGC1α is mechanistically involved in the glucagon medi-
ated stabilization of PRMT1V2 on the protein level, whereas, 
the other hormone crucial in glycemic control, insulin, posts 
minimal effects in this process. The specificity at each step 
of this pathway may prove to be advantageous when aiming 
for targeted effects in future efforts strategizing therapeutic 
intervention against pathological hyperglycemia.
Lastly, our study revealed impressive functional signifi-
cance of this interaction. With deletion of Prmt1 in hepato-
cytes, mice displayed better glycemia control and overall 
improved metabolic health when challenged with STZ injec-
tion or HFD feeding, indicating that PRMT1 played a critical 
role in the regulation of inappropriate hepatic glucose pro-
duction in diabetes. Given that PRMT1V2 was significantly 
induced in the liver of multiple metabolic disease settings 
where liver dysfunction is involved, ongoing drug develop-
ment efforts to identify specific inhibitor for PRMT1 may be 
of great therapeutic potential in the near future.45
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